Acetaminophen Risk Management On Tap For Joint Advisory Panel
This article was originally published in The Tan Sheet
Executive Summary
FDA is looking for risk-management solutions to liver problems linked to the misuse of acetaminophen in OTC and prescription products, and will convene a joint advisory panel to discuss potential steps to take
You may also be interested in...
Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data
A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks
Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data
A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks
Lower Acetaminophen Doses Recommended Despite Cost Impact, Lack Of Data
A joint advisory committee recommended as a "top priority" that FDA lower the maximum single and daily dose of acetaminophen, despite inconclusive data that the current dose poses significant hepatotoxicity risks